{
    "clinical_study": {
        "@rank": "87612", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the efficacy of picibanil sclerotherapy in children with macrocystic\n      lymphangioma."
        }, 
        "brief_title": "Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations", 
        "condition": "Lymphatic Malformations", 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Lymphangioma", 
                "Lymphangioma, Cystic", 
                "Lymphatic Abnormalities"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a  multicenter study. Patients are stratified according to prior\n      treatment (no prior treatment vs prior surgical treatment) and geographic area.\n\n      Patients who meet all study criteria are put in the \"Immediate Treatment Group.\" Patients\n      receive an intralesional injection of picibanil (OK432) with the aid of ultrasonography or\n      transillumination for localization of cysts.  Treatment repeats every 6-8 weeks for a total\n      of up to 4 injections.\n\n      After completion of treatment, patients are followed at 6 months, 1 year, and 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Diagnosis of macrocystic lymphangioma of the head and/or neck Cystic spaces at least\n             2.0 mL confirmed by radiographic imaging (MRI or CT) Mixed lymphangiomas (macrocystic\n             and microcystic disease) allowed if macrocystic component comprises at least 50% of\n             the total disease burden\n\n          -  No mixed hemangioma-lymphangioma lesions\n\n          -  At least 6 months since prior surgery for lymphangioma\n\n        --Patient Characteristics--\n\n          -  Hematopoietic: No clinically significant hematologic disease No hemodynamic\n             instability\n\n          -  Hepatic: No clinically significant hepatic disorder\n\n          -  Renal: No clinically significant renal disease No personal or family history of\n             post-streptococcal glomerulonephritis\n\n          -  Cardiovascular: No personal or family history of rheumatic heart disease\n\n          -  Pulmonary: No respiratory failure\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  No history of allergy to penicillin\n\n          -  No concurrent temperature of 100.5 degrees or greater\n\n          -  No active upper respiratory infection\n\n          -  No personal or family history of obsessive-compulsive or tic disorders\n\n          -  No personal or family history of PANDA (pediatric autoimmune neuro- psychiatric\n             disorder associated with streptococcal infections)\n\n          -  No history of hypersensitivity to iodine, Omnipaque, or gadolinium (if fluoroscopy is\n             considered necessary)\n\n          -  No history of poor health (including congenital disorders, chronic diseases, or\n             immunologic dysfunction)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 2, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00010452", 
            "org_study_id": "199/15706", 
            "secondary_id": "UIHC-FDR001774"
        }, 
        "intervention": {
            "description": "Up to .2 mg per injection, given intralesionally every 6-8 weeks", 
            "intervention_name": "picibanil", 
            "intervention_type": "Drug", 
            "other_name": "OK432"
        }, 
        "intervention_browse": {
            "mesh_term": "Picibanil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "cystic hygroma", 
            "lymphangiomas", 
            "lymphatic malformations"
        ], 
        "lastchanged_date": "March 28, 2008", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92123"
                    }, 
                    "name": "Children's Associated Medical Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80218"
                    }, 
                    "name": "Children's Hospital of Denver"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia"
                    }, 
                    "name": "Childrens National Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33701"
                    }, 
                    "name": "All Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242"
                    }, 
                    "name": "University of Iowa Hospitals and Clinics"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55404"
                    }, 
                    "name": "Children's Hospitals and Clinics - Minneapolis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Syracuse", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "13210"
                    }, 
                    "name": "SUNY Upstate Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon"
                    }, 
                    "name": "Oregon Health Sciences University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "Vanderbilt University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Texas Pediatric Otolaryngology Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23507"
                    }, 
                    "name": "Children's Hospital of the Kings Daughter"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792-0001"
                    }, 
                    "name": "University of Wisconsin Hospital and Clinics"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53201"
                    }, 
                    "name": "Children's Hospital of Wisconsin"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Treatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter Trial", 
        "overall_official": {
            "affiliation": "University of Iowa", 
            "last_name": "Richard J Smith", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "to establish whether OK432 sclerotherapy is an effective form of treatment for lymphatic malformations versus the traditional form of treatment, which is surgical excision.", 
            "safety_issue": "Yes", 
            "time_frame": "indefinate"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00010452"
        }, 
        "responsible_party": {
            "name_title": "Richard JH Smith, MD", 
            "organization": "University of Iowa Health Care"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "Chugai Pharmaceutical", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Iowa", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2000", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2008"
    }, 
    "geocoordinates": {
        "All Children's Hospital": "27.773 -82.64", 
        "Children's Associated Medical Group": "32.715 -117.157", 
        "Children's Hospital of Denver": "39.739 -104.985", 
        "Children's Hospital of Wisconsin": "43.039 -87.906", 
        "Children's Hospital of the Kings Daughter": "36.851 -76.286", 
        "Children's Hospitals and Clinics - Minneapolis": "44.98 -93.264", 
        "Childrens National Medical Center": "38.895 -77.036", 
        "Oregon Health Sciences University": "45.523 -122.676", 
        "SUNY Upstate Medical University": "43.048 -76.147", 
        "Texas Pediatric Otolaryngology Center": "29.76 -95.369", 
        "University of Iowa Hospitals and Clinics": "41.661 -91.53", 
        "University of Wisconsin Hospital and Clinics": "43.073 -89.401", 
        "Vanderbilt University": "36.166 -86.784"
    }
}